Our Services
Medical Information
Helpful Resources
Published on: 3/18/2026
Newer and experimental IBD drug side effects include infections, GI symptoms that can mimic flares (including drug-induced colitis), blood clots with some JAK inhibitors, liver and cholesterol changes, and injection or infusion reactions. Long-term cancer risk remains under study.
If your gut is still failing on treatment, causes may include a mismatch to your immune profile, anti-drug antibodies, overlapping inflammatory pathways, or infection while immunosuppressed. Modern care addresses this with careful screening, monitoring, precision matching, combination approaches, microbiome strategies, and earlier aggressive treatment. Watch for red flags, know your monitoring plan, and understand when to check for drug-induced colitis or call your care team.
Because IBD symptoms, drug side effects, and infections can look nearly identical, sorting out what's actually driving your symptoms is critical before your next dose or flare escalates. A free, instant, online symptom check can help you clarify what's going on, flag urgent warning signs, and prepare a clearer picture to share with your care team—so you can act quickly and confidently on next steps.
Reviewed for medical accuracy: 07/10/2026
Inflammatory bowel disease (IBD)—which includes Crohn's disease and ulcerative colitis—is a chronic inflammatory condition that affects millions of people worldwide. When standard treatments fail, many patients turn to newer or experimental therapies. These drugs can be promising. But like all powerful medications, they can come with risks.
Understanding the side effects of experimental IBD drugs is critical. Not to scare you—but to help you make informed, confident decisions with your doctor.
If you're on advanced or experimental therapy and still experiencing symptoms, you're not alone. There are several reasons why your gut may not be responding as expected:
It's important to distinguish between:
If symptoms suddenly worsen after starting a new therapy, it's crucial to identify whether medication itself could be triggering inflammation—check your symptoms for Drug-Induced Colitis using Ubie's free AI-powered tool to better understand what's happening before your next doctor visit.
Experimental or newer IBD drugs often include:
Many of these therapies are approved in recent years or are in late-stage clinical trials. While they are based on strong scientific research, long-term safety data may still be evolving.
Most modern IBD drugs are designed to be more targeted than older immune suppressants. However, because they affect the immune system, side effects can occur.
Here are the most commonly reported side effects of experimental IBD drugs:
Because these medications suppress or modify immune activity, infections are one of the most important risks.
If you develop:
You should speak to a doctor promptly.
Ironically, medications meant to calm gut inflammation can sometimes cause new GI symptoms:
In rare cases, medications can cause drug-induced colitis, which may feel identical to an IBD flare.
Some JAK inhibitors have been associated with:
Risk is generally higher in:
This does not mean the drug is unsafe for everyone. It means careful screening and monitoring are essential.
Some experimental therapies can affect liver function.
Doctors monitor:
Most liver changes are mild and reversible. Rarely, serious liver injury can occur.
Certain JAK inhibitors may increase:
Your provider may monitor lipid levels and manage them if needed.
With biologics, some patients experience:
Severe allergic reactions are rare but possible.
Because many IBD drugs affect immune surveillance, researchers closely monitor long-term cancer risk.
So far:
It's important to balance this against the known risks of uncontrolled IBD, which itself increases cancer risk over time.
Modern IBD care is far more careful and personalized than it was 10–20 years ago.
Before starting experimental therapy, doctors typically:
During treatment, monitoring may include:
This monitoring significantly reduces serious complications.
Most side effects are manageable. However, seek medical care urgently if you experience:
Do not ignore sudden or severe symptoms. Always speak to a doctor about anything that could be life threatening or serious.
New immune-targeting drugs may temporarily shift immune balance. This can sometimes:
However, if symptoms persist beyond a few weeks—or clearly worsen—reassessment is important.
Never assume worsening symptoms are "just part of the process."
It's important to put the side effects of experimental IBD drugs into perspective.
Uncontrolled IBD can lead to:
For many patients, the risk of untreated inflammation is higher than the risk of modern targeted therapy.
Treatment decisions are always about balance.
The future of IBD care is moving toward:
Matching therapy to:
Lower doses of multiple agents rather than high doses of one.
Exploring:
Treating inflammation early to prevent long-term damage.
These approaches aim to reduce both disease activity and medication side effects.
If you suspect your medication may be causing new bowel inflammation, Ubie's free AI-powered Drug-Induced Colitis symptom checker can help you identify patterns and prepare for a more productive conversation with your physician.
The side effects of experimental IBD drugs are real—but they are generally well studied, monitored, and manageable. These medications represent major advances in treatment and have dramatically improved quality of life for many people with Crohn's disease and ulcerative colitis.
The key is not fear—but awareness.
If something feels off, trust your instincts and speak to a doctor. Any symptoms that are severe, rapidly worsening, or potentially life threatening should be evaluated immediately.
Modern IBD care is more personalized and safer than ever. With careful monitoring and open communication, most patients can safely benefit from these newer therapies while minimizing risk.
(References)
* Singh S, et al. New and emerging therapies for inflammatory bowel diseases: what is on the horizon? Expert Rev Clin Immunol. 2021 Jan;17(1):19-35. doi: 10.1080/1744666X.2021.1852654. Epub 2020 Nov 29. PMID: 33207909.
* Maloy KJ, et al. The intestinal epithelial barrier in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):77-91. doi: 10.1038/s41575-020-00366-4. Epub 2020 Nov 16. PMID: 33199898; PMCID: PMC7856108.
* Gecse KB, et al. New therapeutic approaches in inflammatory bowel diseases beyond TNFα. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):191-203. doi: 10.1016/S2468-1253(19)30342-1. Epub 2019 Nov 27. PMID: 31787595.
* Roda G, et al. Emerging Treatment Modalities for Inflammatory Bowel Disease. Gastroenterology. 2020 Mar;158(4):1122-1136. doi: 10.1053/j.gastro.2019.12.030. Epub 2020 Jan 9. PMID: 31926227.
* Liu Z, et al. Gut microbiota-targeted therapies for inflammatory bowel disease: recent advances and future perspectives. Gut Microbes. 2023 Jan-Dec;14(1):2171241. doi: 10.1080/19490976.2023.2171241. PMID: 36762391; PMCID: PMC9930776.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.